Allergy
Conditions
Interventions
Provocation with ASA
1 day of 4 hours, patients will receive three placebo tablets
1 day of 4 hours, subjects will receive ASA in three ascending dosages
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Systemic mastocytosis, according to WHO criteria.
Exclusion criteria
Exclusion criteria: Severe of uncontrolled asthma (FEV1<70%), nasal polyps, chronic rhinosinusitis, previous anaphylaxis due to NSAID's, patients who are not able to provide follow-up information, patients who are not deemed capable of handling possible delayed anaphylaxis at home.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - frequency of allergic reactions due to ASA ingestion - severity of anaphylaxis: grading of symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| - measurment of mast cell mediators before and after ASA ingestion; serum trypase levels, plasma 11bèta-PGF2a levels, urine leukotriene E4 levels and urine N-methylhistamine levels. - daily SM-related symptoms: information will be retrieved with questionnaires. - measurement of health-related quality of life of SM patients. | — |
Countries
Netherlands
Outcome results
None listed